Literature DB >> 15311098

Trends in blood pressure control and antihypertensive treatment in clinical practice: the Brisighella Heart Study.

Claudio Borghi1, Ada Dormi, S D'Addato, Antonio Gaddi, Ettore Ambrosioni.   

Abstract

OBJECTIVES: To assess trends in blood pressure (BP) awareness, control, treatment and use of different antihypertensive medications in a cohort of hypertensive patients.
DESIGN: This study summarizes the results of a 12-year observation (1984-1996) of a cohort of 940 hypertensive patients from the population of 2329 participants to the Brisighella Heart Study (BHS). Primary outcome measures were the extent of BP control (systolic/diastolic BP < 140/90 mmHg) and prevalence of the use of various antihypertensive medications.
RESULTS: From 1984 to 1996 the proportion of patients aware of elevated BP and treated for hypertension rose from 73 to 88% and from 43.8 to 50.3% in men, and from 77 to 87% and from 50 to 56.6% in women (P < 0.001 for all). The rate of BP control increased from 7.5 to 17.4% in men (P < 0.001) and from 7.3 to 18.5% in women (P < 0.001). This occurred with increased use of combination therapy (+0.2 drugs/person) and with a decline in the use of diuretics (-38.2% men and -28% women; P < 0.001) and an increase in use of calcium-channel blockers (CCBs) (24.2% in men and 12.2% in women; P < 0.001) and angiotensin-converting enzyme (ACE) inhibitors (30.7% in men and 30.8% in women; P < 0.001) as first-line drugs. The improved BP control was associated with a lower rate of fatal and non-fatal cardiovascular (CV) events.
CONCLUSIONS: The results of this observational study confirm that the rate of BP control can be improved in daily clinical practice by increasing the use of drug combinations, as well as by the first-line prescription of ACE inhibitors and CCBs [and probably angiotensin II receptor inhibitors (ARBs)].

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15311098     DOI: 10.1097/00004872-200409000-00014

Source DB:  PubMed          Journal:  J Hypertens        ISSN: 0263-6352            Impact factor:   4.844


  14 in total

1.  ABCA1-dependent serum cholesterol efflux capacity inversely correlates with pulse wave velocity in healthy subjects.

Authors:  Elda Favari; Nicoletta Ronda; Maria Pia Adorni; Francesca Zimetti; Paolo Salvi; Matteo Manfredini; Franco Bernini; Claudio Borghi; Arrigo F G Cicero
Journal:  J Lipid Res       Date:  2012-10-28       Impact factor: 5.922

2.  Safety and tolerability of an olmesartan medoxomil-based regimen in patients with stage 1 hypertension: a randomized, double-blind, placebo-controlled study.

Authors:  Steven G Chrysant
Journal:  Clin Drug Investig       Date:  2010       Impact factor: 2.859

3.  Imputing observed blood pressure for antihypertensive treatment: impact on population and genetic analyses.

Authors:  Brinda K Rana; Anish Dhamija; Matthew S Panizzon; Kelly M Spoon; Terrie Vasilopoulos; Carol E Franz; Michael D Grant; Kristen C Jacobson; Kathleen Kim; Michael J Lyons; Jeanne M McCaffery; Phyllis K Stein; Hong Xian; Daniel T O'Connor; William S Kremen
Journal:  Am J Hypertens       Date:  2014-02-14       Impact factor: 2.689

4.  Clinical management of patients with hypertension and high cardiovascular risk: main results of an Italian survey on blood pressure control.

Authors:  Giuliano Tocci; Claudio Borghi; Massimo Volpe
Journal:  High Blood Press Cardiovasc Prev       Date:  2013-10-23

Review 5.  Do we need more than just powerful blood pressure reductions? New paradigms in end-organ protection.

Authors:  Domenico Galzerano; Cristina Capogrosso; Sara Di Michele; Emanuele Bobbio; Paola Paparello; Carlo Gaudio
Journal:  Vasc Health Risk Manag       Date:  2010-08-09

Review 6.  Using fixed-dose combination therapies to achieve blood pressure goals.

Authors:  Steven G Chrysant
Journal:  Clin Drug Investig       Date:  2008       Impact factor: 2.859

7.  Blood pressure outcomes in patients receiving angiotensin II receptor blockers in primary care: a comparative effectiveness analysis from electronic medical record data.

Authors:  C Venkata S Ram; Krishnan Ramaswamy; Chunlin Qian; Joe Biskupiak; Amy Ryan; Ruth Quah; Patricia A Russo
Journal:  J Clin Hypertens (Greenwich)       Date:  2011-10-18       Impact factor: 3.738

8.  The impact of an individualized risk-adjusted approach on hypertension treatment in primary care.

Authors:  Stefan Zechmann; Oliver Senn; Fabio Valeri; Stefan Neuner-Jehle; Thomas Rosemann; Sima Djalali
Journal:  J Clin Hypertens (Greenwich)       Date:  2017-01-06       Impact factor: 3.738

Review 9.  Achieving blood pressure goals: why aren't we?

Authors:  William C Cushman; Jan Basile
Journal:  J Clin Hypertens (Greenwich)       Date:  2006-12       Impact factor: 3.738

10.  Results of an olmesartan medoxomil-based treatment regimen in hypertensive patients.

Authors:  Suzanne Oparil; Steven G Chrysant; Dean Kereiakes; Jianbo Xu; Kathleen J Chavanu; William Waverczak; Robert Dubiel
Journal:  J Clin Hypertens (Greenwich)       Date:  2008-12       Impact factor: 3.738

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.